Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 3/20 | 0.52 |
| ▸ | FDPS | P14324 | 2/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12060351 | 0.92 | GGPS1 (0.56) | GGPS1FDPSPABPC1KMT2AATM | |
| SCHEMBL12048259 | 0.85 | GGPS1 (0.52) | GGPS1FDPSKDM4E | |
| SCHEMBL12048207 | 0.84 | GGPS1 (0.51) | GGPS1FDPS | |
| SCHEMBL12048200 | 0.84 | GGPS1 (0.51) | GGPS1FDPS | |
| SCHEMBL12048195 | 0.84 | GGPS1 (0.51) | GGPS1FDPS | |
| SCHEMBL12048186 | 0.84 | GGPS1 (0.51) | GGPS1FDPSKMT2A | |
| SCHEMBL12048150 | 0.84 | GGPS1 (0.46) | GGPS1FDPSKDM4EALDH1A1 | |
| SCHEMBL12048172 | 0.83 | FDPS (0.50) | GGPS1FDPS | |
| SCHEMBL12048146 | 0.83 | GGPS1 (0.76) | GGPS1FDPSLMNAKDM4EALDH1A1 | |
| SCHEMBL12048171 | 0.82 | GGPS1 (0.49) | GGPS1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196835-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-08-02 | — | — | US | disclosed |
| US-8071573-B2 | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, A BODY CORPORATE AND POLITIC OF THE STATE OF ILLINOIS (US) | 2011-12-06 | — | — | US | disclosed |
| US-7358361-B2 | Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196835-A1 | ENZYME INHIBITING COMPOUNDS AND METHODS | COASY, FADS2, FDPS | GGPS1 20/4885FDPS 3/4885PABPC1 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.